Estrella Immunopharma, Inc.
No SEC Form 4 filings for $ESLA in the last 30 days.
See all $ESLA insider activity →Estrella Immunopharma (ESLA) reported that the first patient in the expansion phase of its STARLIGHT-1 trial tolerated two doses of EB103 T cells with no serious adverse events. Earlier high-dose escalation showed 100% complete response at Month 1 in evaluable patients, according to the company.
Estrella Immunopharma (ESLA) said University Hospitals Cleveland Medical Center has been added as the fourth site for its Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. The multi-center expansion will assess safety and efficacy at the Phase II dose. ESLA stock closed at $0.70.
Estrella Immunopharma, Inc. (ESLA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001844417 0001844417 2026-06-29 2026-06-29 0001844417 ESLA:CommonStockParValue0.0001PerShareMember 2026-06-29 2026-06-29 0001844417 ESLA:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:share
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ESLA (Estrella Immunopharma, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ESLA coverage spans technology, financial news and corporate actions.
Early tolerability data reduces safety concerns and may lift the stock.
Adds a new clinical enrollment location for EB103, which can modestly improve trial recruitment and near-term execution risk.
Routine annual-meeting voting results; no operational or financial guidance changes disclosed.
The filing reveals that Eureka Therapeutics owns approximately 59.3% of ESLA, classifying it as a controlled company. CEO and CFO salaries are disclosed, indicating transparency but no immediate financial concerns. The high ownership stake could influence company decisions and stock performance.
The Nasdaq notice for Estrella Immunopharma indicates potential short-term operational and regulatory concerns, but does not immediately threaten its listing or financial stability.
AlphAI scores every news story that mentions ESLA with an AI model for sentiment and relevance, and aggregates insider trades from Estrella Immunopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Estrella Immunopharma (ESLA) reported that the first patient in the expansion phase of its STARLIGHT-1 trial tolerated two doses of EB103 T cells with no serious adverse events. Earlier high-dose escalation showed 100% complete response at Month 1 in evaluable patients, according to the company.
1 min readEstrella Immunopharma (ESLA) said University Hospitals Cleveland Medical Center has been added as the fourth site for its Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. The multi-center expansion will assess safety and efficacy at the Phase II dose. ESLA stock closed at $0.70.
3 min readEstrella Immunopharma, Inc. (ESLA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001844417 0001844417 2026-06-29 2026-06-29 0001844417 ESLA:CommonStockParValue0.0001PerShareMember 2026-06-29 2026-06-29 0001844417 ESLA:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:share
2 min readEstrella Immunopharma (NASDAQ: ESLA) filed an amended annual report (10-K/A) for the fiscal year ended December 31, 2025, providing detailed disclosures on board composition, executive compensation, beneficial ownership, and auditor matters. The filing revealed that CEO Dr. Cheng Liu and CFO Peter Xu each earned $250,962 in salary for 2025, and that Eureka Therapeutics, Inc. beneficially owns approximately 59.3% of Estrella's common stock, classifying it as a "controlled company" under Nasdaq rules.
3 min readEstrella Immunopharma, Inc. received a Nasdaq notice for non-compliance with the rule requiring annual shareholder meetings, having 45 days to submit a compliance plan. The company plans to hold its meeting in April 2026 but acknowledges no assurance of Nasdaq's approval. This notice does not immediately affect its stock listing, and follows recent news of a successful $8 million direct offering and clearance for its EB103 cancer therapy to Phase II clinical trials.
3 min read
